BIO-Europe 2022 in Leipzig, Germany, new EU regulation of clinical trials, gene and cell therapy, patient diversity in clinical trials

Key Takeaways from BIO-Europe 2022

In the wake of relaxed post-pandemic restrictions, events such as BIO-Europe 2022 have returned in full force. Nicole Brenna, US Business Development Director, represented Cromos Pharma at the BIO-Europe 2022 Conference, hosted in Leipzig, Germany. These are her key takeaways from the event.

‘The return to BIO-Europe after the absence that the COVID-19 Pandemic wrought was a welcome change and hot topic amongst attendees. The conference brought a high level of interest, and with assistance of the partnering system, attendees were able to have productive one-on-one meetings. It can be said that many of the discussions were centered around introducing new EU regulations. Particularly when and how everyone is affected and what preparations they are undergoing. Moreover, this was heavily discussed amongst both sponsors and CROs.

While the EU regulations were a hot-button topic, patient diversity remains a consistent subject concerning clinical trials. This subject continues to gather interest, particularly with many companies seeking to create more extensive and involved research studies in the future. 

Finally, the last matter that was also entirely at the forefront of many companies’ minds was cell and gene therapies. All in all, the conference was fantastic with many insightful and diverse speakers, and once again, it was good to go back to an offline modality.’ –  says Nicole Brenna

BIO-Europe 2022

The BIO-Europe 2022 conference was an exciting and professional affair with over 5,000 delegates from over 2,500 companies, representing 66 nations. Furthermore, a testament to its success, over 25,000 in-person and virtual partnering meetings took place during the conference. 

About Cromos Pharma

Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.

Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye resulting in rapid patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.

We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.

Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.

If you have any questions or want to find out more about how Cromos Pharma can support your next clinical program, please get in touch with us by emailing



To arrange an introductory meeting and find out how our experience can benefit your next clinical project.